Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q09470: Variant p.Phe184Cys

Potassium voltage-gated channel subfamily A member 1
Gene: KCNA1
Feedback?
Variant information Variant position: help 184 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Phenylalanine (F) to Cysteine (C) at position 184 (F184C, p.Phe184Cys). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and aromatic (F) to medium size and polar (C) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In EA1; alters voltage dependence and kinetics of activation though not of C-type inactivation. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 184 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 495 The length of the canonical sequence.
Location on the sequence: help GPARVIAIVSVMVILISIVI F CLETLPELKDDKDFTGTVHR The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         GPARVIAIVSVMVILISIVIFCLETLPELKDDKDFTGTVHR

Mouse                         GPARVIAIVSVMVILISIVIFCLETLPELKDDKDFTGTIHR

Rat                           GPARVIAIVSVMVILISIVIFCLETLPELKDDKDFTGTIHR
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 495 Potassium voltage-gated channel subfamily A member 1
Transmembrane 165 – 186 Helical; Name=Segment S1
Mutagenesis 177 – 177 I -> N. Slows down N-type inactivation of heteromeric channels formed by KCNA1 and KCNA4.



Literature citations
Identification of two new KCNA1 mutations in episodic ataxia/myokymia families.
Browne D.L.; Brunt E.R.P.; Griggs R.C.; Nutt J.G.; Gancher S.T.; Smith E.A.; Litt M.;
Hum. Mol. Genet. 4:1671-1672(1995)
Cited for: VARIANTS EA1 PHE-174; CYS-184 AND ASP-325; Episodic ataxia results from voltage-dependent potassium channels with altered functions.
Adelman J.P.; Bond C.T.; Pessia M.; Maylie J.;
Neuron 15:1449-1454(1995)
Cited for: CHARACTERIZATION OF VARIANTS EA1 CYS-184; ASP-325 AND ALA-408; FUNCTION; TRANSPORTER ACTIVITY;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.